Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes

被引：6

作者：

Zeidan, Amer M. ^{[1
]}

Klink, Andrew J. ^{[2
]}

McGuire, Michael ^{[3
]}

Feinberg, Bruce ^{[2
]}

机构：

[1] Yale Univ, Dept Internal Med, 333 Cedar St,POB 208028, New Haven, CT 06520 USA

[2] Cardinal Hlth Specialty Solut, Dublin, OH USA

[3] Celgene Corp, Summit, NJ USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 08期

关键词：

Azacitidine; decitabine; lenalidomide; myelodysplastic syndromes; retrospective;

D O I：

10.1080/10428194.2018.1551538

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lenalidomide and hypomethylating agents (HMAs) azacitidine and decitabine are approved for treating myelodysplastic syndromes (MDS), but optimal sequencing is unclear. Adults with MDS were identified from a US payer claims database (Inovalon MORE2 Registry) to compare outcomes with lenalidomide followed by HMA (LEN-HMA) or HMA followed by lenalidomide (HMA-LEN). There were 96 patients who received LEN-HMA and 89 who received HMA-LEN. LEN-HMA-treated patients had a longer time to second treatment discontinuation (29.0 vs. 19.0months, p=.009; adjusted hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.29-0.91, p=.023). LEN-HMA-treated patients had a longer median time to insurance disenrollment (22.4 vs. 16.1months, p<.001; adjusted HR 0.64, 95% CI: 0.44-0.92, p=.017), used as a proxy for survival. Longer treatment duration and survival with LEN-HMA support first-line use of lenalidomide in MDS in sequence with HMAs.

引用

页码：2050 / 2055

页数：6

共 12 条

[1] Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research [J].

Carnahan, Ryan M. .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 :90-99

[2] Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes [J].

Clara, Joseph A. ;

Sallman, David A. ;

Padron, Eric .

CANCER BIOLOGY & MEDICINE, 2016, 13 (03) :360-372

[3] Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology [J].

Greenberg, Peter L. ;

Stone, Richard M. ;

Al-Kali, Aref ;

Barta, Stefan K. ;

Bejar, Rafael ;

Bennett, John M. ;

Carraway, Hetty ;

De Castro, Carlos M. ;

Deeg, H. Joachim ;

DeZern, Amy E. ;

Fathi, Amir T. ;

Frankfurt, Olga ;

Gaensler, Karin ;

Garcia-Manero, Guillermo ;

Griffiths, Elizabeth A. ;

Head, David ;

Horsfall, Ruth ;

Johnson, Robert A. ;

Juckett, Mark ;

Klimek, Virginia M. ;

Komrokji, Rami ;

Kujawski, Lisa A. ;

Maness, Lori J. ;

O'Donnell, Margaret R. ;

Pollyea, Daniel A. ;

Shami, Paul J. ;

Stein, Brady L. ;

Walker, Alison R. ;

Westervelt, Peter ;

Zeidan, Amer ;

Shead, Dorothy A. ;

Smith, Courtney .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (01) :60-87

[4]

KIM H, 2015, BLOOD, V126, P1687

[5] Efficacy of lenalidomide in myelodysplastic syndromes [J].

List, A ;

Kurtin, S ;

Roe, DJ ;

Buresh, A ;

Mahadevan, D ;

Fuchs, D ;

Rimsza, L ;

Heaton, R ;

Knight, R ;

Zeldis, JB .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06) :549-557

[6] Myelodysplastic syndromes - Incidence and survival in the United States [J].

Ma, Xiaomei ;

Does, Monique ;

Raza, Azra ;

Mayne, Susan T. .

CANCER, 2007, 109 (08) :1536-1542

[7]

National Cancer Institute, 2012, SURV EP END RES PROG

[8] Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents [J].

Santini, Valeria ;

Almeida, Antonio ;

Giagounidis, Aristoteles ;

Groepper, Stefanie ;

Jonasova, Anna ;

Vey, Norbert ;

Mufti, Ghulam J. ;

Buckstein, Rena ;

Mittelman, Moshe ;

Platzbecker, Uwe ;

Shpilberg, Ofer ;

Ram, Ron ;

del Canizo, Consuelo ;

Gattermann, Norbert ;

Ozawa, Keiya ;

Risueno, Alberto ;

MacBeth, Kyle J. ;

Zhong, Jianhua ;

Seguy, Francis ;

Hoenekopp, Albert ;

Beach, C. L. ;

Fenaux, Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) :2988-+

[9] Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS) [J].

Uno, Hajime ;

Cronin, Angel M. ;

Wadleigh, Martha ;

Schrag, Deborah ;

Abel, Gregory A. .

LEUKEMIA RESEARCH, 2014, 38 (12) :1420-1424

[10]

Wade RL, 2017, INT SOC PHARM OUTC R

← 1 2 →